diaTribe®

diaTribe® The mission of the diaTribe Foundation is to support individuals with diabetes and prediabetes and to advocate for effective action.

The mission of the diaTribe Foundation is to help people with diabetes and prediabetes and to advocate for action. diaTribe is dedicated to bringing people with diabetes to the conversation on regulatory issues, connecting the field and the diabetes community, and changing the narrative around diabetes. diaTribe Learn: We’re committed to helping people with diabetes live happier, healthier, and mo

re hopeful lives through our diaTribe publication, Learn, which reaches over 6 million people annually. Our writing team has deep insights into the patient experience and closely covers the latest research, treatments, and initiatives in diabetes. Our tagline is “Making Sense of Diabetes.”

Time in Range: Everyone with diabetes deserves to have the tools, therapies, and technologies to live their best life. The diaTribe Foundation formed The Time in Range Coalition with a multi-stakeholder group of foundations, non-profit organizations, researchers, people with diabetes, clinicians, and industry. Our goal is to establish time in range as an essential part of diabetes care and to make time in range accessible to all people with diabetes and their care teams. This involves work in multiple areas, including regulatory, clinical, research, and patient education. Stigma: We aim to reduce the impact of diabetes on society and improve the lives of people with diabetes by fostering an understanding of the disease, eliminating misplaced blame, and ensuring access to care. We believe that addressing diabetes stigma is an essential missing element of effective diabetes care and mental wellness, and we aim to change that through the work of our program, dStigmatize. Our team is fiercely committed to improving the lives of people with diabetes. We are all personally touched by this disease, and some of us have it ourselves. Our work is a labor of love, so we invite you to join the diaTribe.

We're bringing you exclusive coverage from the American Diabetes Association’s 2026 conference in New Orleans! Day 2 was...
07/06/2026

We're bringing you exclusive coverage from the American Diabetes Association’s 2026 conference in New Orleans! Day 2 was packed with more incredible research advancing the field of diabetes care.

💡 Though still very early in the research phase, data indicate that SAB-142 can be administered multiple times over a person’s lifetime, suggesting that it could potentially delay type 1 diabetes progression indefinitely. The company is now recruiting children and adults who have recently been diagnosed with stage 3 type 1 diabetes for a larger clinical trial to test the effectiveness of the drug in delaying disease progression and preserving insulin production.

💡 A new ultra-long-lasting GLP-1 option is berobenatide, which has a slightly modified structure that allows it to stay active in the body longer than currently available options. In an early research trial, 133 people with overweight or obesity and type 2 diabetes took a placebo or one of four doses of berbobenatide every week for seven months.
At the highest dose, participants lost an average of 15% of their body weight and lowered their A1C by 2.2%.

Get daily updates on the latest news from the conference at https://learn.diatribe.org/daily-diabetes-drop.

⭐ Omnipod 6 News?! ⭐ Insulet's next-generation Omnipod 6 includes updates intended to keep users in automated mode more ...
07/06/2026

⭐ Omnipod 6 News?! ⭐ Insulet's next-generation Omnipod 6 includes updates intended to keep users in automated mode more often, including during hypoglycemia, and has an advanced algorithm that can deliver more insulin when needed.

The system uses a glucose target of 100 mg/dL (a recent update allows Omnipod 5 users to use this lower 100 mg/dL target).

A new study presented at ADA, which included 132 adults with type 1 or type 2 diabetes and children with type 1, found that the Omnipod 6 increased time in range (70-180 mg/dL) compared to the current Omnipod 5. People in the study used each system for four weeks. With Omnipod 6, time in range increased slightly to 73%, compared with 70% on Omnipod 5. Time in tight range (70-140 mg/dL) also rose from about 47% with Omnipod 5 to 52% with Omnipod 6. For people considering an AID system, these findings suggest the upgraded Omnipod may help them spend more of the day in range while reducing manual meal dosing.

We have more exciting updates from ADA on the way! Sign up to get the latest delivered right to your inbox: https://learn.diatribe.org/daily-diabetes-drop

We're at the 2026 ADA Scientific Sessions in New Orleans! Day 1 was packed with diabetes news and meaningful conversatio...
06/06/2026

We're at the 2026 ADA Scientific Sessions in New Orleans! Day 1 was packed with diabetes news and meaningful conversations about the latest advancements in diabetes care.

📉 Cuts to federal research funding could slow future progress for people with type 1 and type 2 diabetes, especially in communities already facing barriers to care. NIH-supported research has led to life-changing treatments and care for people with type 1 and 2 diabetes, including the development of Tzield – the first ever treatment to delay the onset of type 1 diabetes. Read the editorial: https://diatribenews.org/43gqoMj

⌚ Tracking your physical activity with devices like smartphones and smartwatches may provide a more accurate picture of how much exercise you are getting, and in turn, help reduce the risk of conditions like type 2 diabetes down the road.

Get daily updates on the latest news from the conference: https://diatribenews.org/4nzHMn9

#

🚨 Big news for people with type 1 diabetes who are using or are interested in using a GLP-1! 35 new recommendations have...
05/06/2026

🚨 Big news for people with type 1 diabetes who are using or are interested in using a GLP-1! 35 new recommendations have been published for use of GLP-1s and GLP-1/GIPs in the management of T1D, aimed to make the process easier and safer! Learn more at https://diatribenews.org/4e01m8Y.

02/06/2026

Can short films help people feel more connected?

We’ve seen how they can! That’s why we’re proud that a Spoonful of Laughter film, “The Bad 1,” which explores loneliness and connection through the lens of diabetes, will be featured in the 10th Anniversary Season of Project UnLonely Films, launching June 8th.

Curated by The Foundation for Art & Healing, this powerful collection of short films raises awareness of loneliness, helps reduce stigma, and sparks connecting conversations.

Why short films?
✅ They’re entertaining and easy to watch
✅ They can help viewers feel seen
✅ They measurably increase empathy
✅ They inspire authentic dialogue

Here’s what’s so special about the Project UnLonely Films collection:
⭐High-quality and thoughtfully curated for 10 years
🩵Humanizes and demystifies loneliness
📽️Easy to stream and screen

From comedies and dramas to animations and documentaries, there’s something for everyone!

Join the Project UnLonely Films community to start watching, reflecting, and connecting and to get notified when Season 10 goes live: https://www.artandhealing.org/puf-get-access/

The diaTribe Foundation 2025 Impact Report is here! At diaTribe, our mission has always been bigger than awareness — it’...
01/06/2026

The diaTribe Foundation 2025 Impact Report is here! At diaTribe, our mission has always been bigger than awareness — it’s about changing lives, improving access and health, amplifying lived experience voices, and creating a better future of diabetes management.

We invite you to read our impact report and be inspired by our immense impact from our editorial diaTribe Learn newsletter, to the Time in Range Coalition, and to our stigma platform, dstigmatize: https://diatribe.org/foundation/impact-reports

See what’s possible when compassion meets action. Together, we are creating a better future for everyone affected by diabetes.

🚨 Afrezza has been approved for children 6 and older! Today, the FDA approved the inhaled insulin for children above 6 y...
29/05/2026

🚨 Afrezza has been approved for children 6 and older!

Today, the FDA approved the inhaled insulin for children above 6 years old who have type 1 or type 2 diabetes. This is a big step in expanded options for youth living with diabetes.

To get news like this straight to your inbox, sign up for the daily drop newsletter at https://diatribenews.org/4nzHMn9.

Diabetes impacts everyone differently—especially when it comes to managing your diabetes AND your wellbeing!! We partner...
28/05/2026

Diabetes impacts everyone differently—especially when it comes to managing your diabetes AND your wellbeing!! We partnered with Diabetes Action Canada to put together some tips made for people with diabetes, by people with diabetes.

Download this infographic and more at https://diatribenews.org/4e9QAhF.

⚠️ URGENT news for users of Omnipod systems ⚠️ Insulet has issued a Medical Device Correction for specific lots of Omnip...
27/05/2026

⚠️ URGENT news for users of Omnipod systems ⚠️

Insulet has issued a Medical Device Correction for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a tear in the tubing. Find out if your pods have been affected at omnipod.com.

To get news like this each day, sign up for the free daily drop newsletter at https://learn.diatribe.org/daily-diabetes-drop.

Address

2352 Market Street #B
CA
94114

Opening Hours

Monday 09:00 - 17:00
Tuesday 09:00 - 17:00
Wednesday 09:00 - 17:00
Thursday 09:00 - 17:00
Friday 09:00 - 17:00

Telephone

+14152419500

Website

Alerts

Be the first to know and let us send you an email when diaTribe® posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to diaTribe®:

Shortcuts

  • Want your organization to be the top-listed Non Profit Organization?

Share